Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide in Chinese Participants With Non-Metastatic Castration-Resistant Prostate Cancer
NCT04108208Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2019
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of apalutamide in castration-resistant prostate cancer (CRPC), sponsored by Janssen Pharmaceutical. Started Dec 2019; status: completed.
02
Drugs
apalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT04108208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04108208.